ALX Oncology Holdings Inc. (ALXO): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALXO Stock Price Chart Interactive Chart >
ALXO Price/Volume Stats
|Current price||$8.23||52-week high||$81.19|
|Prev. close||$8.09||52-week low||$5.82|
|Day high||$8.31||Avg. volume||496,050|
|50-day MA||$9.18||Dividend yield||N/A|
|200-day MA||$26.71||Market Cap||334.80M|
ALX Oncology Holdings Inc. (ALXO) Company Bio
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia on April 1, 2020 and is headquartered in Burlingame, CA.
Most Popular Stories View All
ALXO Latest News Stream
|Loading, please wait...|
ALXO Latest Social Stream
View Full ALXO Social Stream
Latest ALXO News From Around the Web
Below are the latest news stories about Alx Oncology Holdings Inc that investors may wish to consider to help them evaluate ALXO as an investment opportunity.
How do you make sense of the current market conditions? We came off a strong bull year for stocks with the worst January in a long time – but the month ended, and February started with the best two-day action since April 2000. And in a quirk, that investors should note, small-cap stocks are showing strong signs of being heavily oversold. Small-caps took a harder hit in January’s swoon than the market giants, and according to JPMorgan's Chief Global Markets Strategist Marko Kolanovic, investors s
Investment company HC Advisors, LLC (Current Portfolio) buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, Amgen Inc, Dyne Therapeutics Inc, UnitedHealth Group Inc, sells Netflix Inc, Invesco S&P 500 Equal Weight ETF, PIMCO Energy & Tactical Credit Opportunities, Pinduoduo Inc, Alphabet Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HC Advisors, LLC.
The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.
The FDA has granted Orphan Drug Designation to ALX Oncology Holdings Inc's (NASDAQ: ALXO) evorpacept for gastric cancer and gastroesophageal junction cancer. In ASPEN-01, patients with >2L HER2 positive gastric (n=18) treated with evorpacept combined with trastuzumab plus ramucirumab and paclitaxel demonstrated an initial objective response rate of 72.2% with a median duration of response of 14.8 months and a median overall survival of 17.1 months. Related content: Benzinga's Full FDA Calendar.
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation (“ODD”) to evorpacept, a next-generation CD47 blocker, for the treatment of patients with gastric cancer and gastroesophageal junction cancer (collectively “GC”). “Receiving or
ALXO Price Returns